
Phylagen turns environmental microbial DNA into actionable insights for organizations monitoring built and natural environments. The company combines DNA sequencing with machine learning and data analytics to profile the environmental microbiome and detect patterns relevant to contamination, hygiene, and biosurveillance. Phylagen operates as a B2B data analytics / life sciences platform that delivers analytical reports and insights to customers across industries such as manufacturing, food, facility management, and public health. Core technologies include high-throughput DNA sequencing, bioinformatics pipelines, and AI/ML models trained on environmental microbiome datasets. The company targets regulated and operational use cases where microbial monitoring and traceability improve safety, compliance, and operational decisions.

Phylagen turns environmental microbial DNA into actionable insights for organizations monitoring built and natural environments. The company combines DNA sequencing with machine learning and data analytics to profile the environmental microbiome and detect patterns relevant to contamination, hygiene, and biosurveillance. Phylagen operates as a B2B data analytics / life sciences platform that delivers analytical reports and insights to customers across industries such as manufacturing, food, facility management, and public health. Core technologies include high-throughput DNA sequencing, bioinformatics pipelines, and AI/ML models trained on environmental microbiome datasets. The company targets regulated and operational use cases where microbial monitoring and traceability improve safety, compliance, and operational decisions.
Founded: 2014
Headquarters: San Francisco, California
Core product: Environmental DNA sequencing and analytics (Ecology by Phylagen)
Industry: Biotechnology / environmental microbiome analytics
Notable investors: 3M New Ventures, Breakout Ventures, Cultivian Sandbox Ventures, Johnson Controls (strategic)
Environmental microbiome monitoring, contamination detection, hygiene auditing, and biosurveillance for built environments.
2014
Biotechnology
Series A listed on public profiles with date Feb 14, 2019
Reported additional strategic funding rounds through 2021 including a strategic investment from Johnson Controls
“Includes corporate strategic investors and venture funds (examples named: 3M New Ventures, Johnson Controls, Breakout Ventures, Cultivian Sandbox Ventures, AgFunder, Blackhorn Ventures)”